This past January marked a historic turning point for the adrenal community. The Global Adrenal Testing Consortium officially convened its inaugural meeting, bringing together a powerhouse of patient advocates, world-class clinicians, and research scientists.
Our mission is centered on a single, urgent goal: Establishing the new gold standard for cortisol monitoring. For too long, patients living with Adrenal Insufficiency (AI) and Cushing’s Syndrome have relied on delayed, single-point testing that fails to capture the 24-hour reality of cortisol fluctuations.
The “Why” Behind the Consortium
The meeting opened with a poignant reminder of the high stakes. Patient advocate Bill Dodge shared his journey through Cushing’s Syndrome and his extensive experience in clinical studies at the NIH. His story underscored a universal truth: patients aren’t just subjects; they are the most vital partners in research design.
Founder Kirsten Norgaard set the tone for the year ahead:
“This isn’t a product pitch. This is a shared thinking space. We are here to define the clinical and patient needs that the current testing landscape has ignored for decades.”
Key Takeaways & Clinical Gaps
The group dove deep into the limitations of current diagnostic standards. Several “red flags” in the status quo were identified:
- The Snapshot Problem: Current lab methods provide a “snapshot” of the past, whereas adrenal crises require immediate, real-time data.
- Atypical Symptoms: Expert discussion highlighted how patients in crisis are often dismissed because their symptoms (like high blood pressure) don’t fit the “textbook” definition.
- Validation Barriers: We addressed the need for testing that accounts for individual biological variance—including age, gender, and exercise—factors often overlooked in generic wellness monitors.
Advancing Global Research Standards
A major highlight of the discussion was the move toward validated real-time testing. The Consortium is not just looking for “wearables”—we are looking for clinical-grade accuracy. Kirsten Norgaard shared a significant update: The Consortium is currently finalizing a sponsored research proposal with a major medical institution. This partnership will focus on validating emerging real-time technologies against the gold standard of mass spectrometry to ensure any new tools are safe for life-saving medical decisions.
What’s Next?
The energy from January is carrying us directly into our next phase of work:
- Refining Thresholds: We are building a consensus on “validation principles” to determine what constitutes a reliable threshold across different testing systems.
- The March 19th Summit: Our next meeting will focus on reviewing early themes and identifying priority use cases for new cortisol technologies.
- Community Collaboration: Our LinkedIn Group has become the central hub for sharing resources and peer-reviewed studies between sessions.
A Final Thought
The inaugural meeting proved that when you put “People, then Processes,” the path to innovation becomes clear. We are no longer waiting for the future of adrenal care—we are defining it together.
Get Involved: Are you a clinician, researcher, or advocate? Join our LinkedIn Group to help shape the future of cortisol testing.
